On or after 2026-08-05, on the day DEA's temporary scheduling orders publish in the Federal Register, the substances named in FR Doc 2026-13580 and FR Doc 2026-13581 become Schedule I controlled substances. There is no grace period, no sell-through window, and no transition period. Retail sale of a Schedule I substance to the general public is not permitted under the Controlled Substances Act, and anyone holding stock who is not a DEA registrant is expected to surrender it.
That is the short version, and it is deliberately blunt because a lot of what is circulating in this market right now is not. This post sets out what changes, what does not, and what the date means for a buyer as opposed to a seller.
Quick Answer: What Changes and What Does Not
| Question | Answer |
| Is there a grace period? | No. The order is effective on the date it publishes. |
| Is there a sell-through allowance? | No. None appears in the statute or in prior temporary orders. |
| Can retailers sell remaining stock? | No. Retail sale of Schedule I substances to the public is not permitted. |
| What happens to inventory on hand? | Non-registrants are expected to surrender it. |
| Can it be challenged in court? | Not the temporary order. The statute bars judicial review. |
| Is it retroactive? | No. Sales completed before the effective date are not CSA offenses. |
| Is Cat's Claw affected? | Uncaria tomentosa is a different plant and is not named in either notice. |
The Date Is a Floor, Not a Fixed Deadline
DEA's two Notices of Intent published on 2026-07-06. Under 21 U.S.C. 811(h) the resulting order may not issue for at least thirty days after publication, which puts the earliest possible issuance at 2026-08-05.
Two things follow. First, thirty days is a minimum, not a maximum — the order could publish later than 2026-08-05, and the agency's stated intent is to issue it as soon as possible after the window expires. Second, planning around a later date is a bet with no upside. If the order arrives on the earliest day and you assumed otherwise, you are non-compliant with no remedy. If you were ready early and it arrives late, you lost nothing.
The mechanism, including why the thirty days is a restriction on the agency rather than a runway for anyone else, is laid out in how DEA temporary scheduling works under 811(h).
No Grace Period, No Sell-Through
The confusion here usually traces back to a real provision that has been misread. Scheduling orders often do contain thirty-day allowances — but they run to existing DEA registrants and cover paperwork only: labeling and packaging updates, initial inventory, recordkeeping. They are not permission to keep selling. A retailer with no DEA registration gets nothing from them.
The historical record is consistent: prior temporary scheduling orders have taken effect on their publication dates with no wind-down for anyone holding stock. The standard order language states directly that retail sales of Schedule I controlled substances to the general public are not allowed under the CSA, and that possession of any quantity in an unauthorised manner on or after the effective date is unlawful.
It is worth contrasting this with what a genuine transition period looks like. When a legislature actually intends a sell-through, it writes a delayed effective date into the law itself and the industry gets a defined runway. A DEA temporary scheduling order does not have one; it is effective the day it publishes.
The Surrender Obligation
Prior temporary scheduling orders include a disposal-of-stocks section stating that any person who does not desire or is unable to obtain a Schedule I registration must surrender all currently held quantities. Not may. Must.
One honest caveat, because we would rather flag it than let it pass: the Notices of Intent published 2026-07-06 do not themselves contain that handling section. It appears in the final order. The expectation that it will appear is an inference from how prior orders have been drafted, and those are near-identical on this point. Read the actual order the day it publishes.
For anyone holding affected stock past the effective date, the practical options collapse quickly:
- It cannot be sold — retail sale of Schedule I to the public is not permitted.
- It cannot be returned to the supplier — that shipment is itself a distribution of a Schedule I substance by an unregistered person.
- It cannot be exported — the CSA's import and export provisions attach to Schedule I material.
- It must be surrendered, through a DEA-registered reverse distributor or the local DEA Diversion Control field office.
Nobody reimburses the loss. Not DEA, not FDA, and absent a specific contract term, not the brand. Because DEA takes the position that a temporary order is not a "rule," it performs no small-business impact analysis, which means the inventory write-off is never even quantified in the record. We go through what this does to the brands themselves in what happens to 7-OH brands.
Registration Is Not a Workaround
A recurring hope in the trade is that a Schedule I registration would let the business continue. It would not.
DEA's registration categories are manufacturer, distributor, importer, exporter, researcher, analytical laboratory, and instructional activities. A Schedule I distributor registration authorises distribution to other registrants — never to consumers. And because Schedule I means no currently accepted medical use, there is no prescription channel either. There is no lawful retail path for a Schedule I substance, at any registration level.
The Boundary Problem: Orders That Cross the Date
This is the operational trap that catches otherwise careful sellers. The offense is distribution or possession on or after the effective date. The date the order was placed does not matter. The date it was paid does not matter.
Every one of these becomes a Schedule I distribution by an unregistered person if it lands on the wrong side of the line: an order placed before but shipped after, a backorder, a subscription auto-ship, a split shipment where the second parcel goes out late, a dropship instruction sent to a brand partner, and freight already in transit. Delivery must be completed before the effective date, not merely dispatched.
Which leads to the other thing worth saying out loud: a "last chance to stock up" clearance is a bad idea in both directions. Parts of this market are running exactly that campaign right now. It creates the boundary problem above, and it builds a documentary record of the seller's own knowledge that a ban was imminent — exactly the sort of evidence that makes an enforcement posture worse rather than better. We are not running one, and we would treat any vendor running one as telling you something about their judgement.
What This Means If You Are a Buyer
Buying ahead does not create a personal exemption. The concern on the consumer side is possession of a scheduled substance on or after the effective date, so a stockpile purchased in July does not become lawful to hold in September simply because the transaction happened earlier. Anyone telling you otherwise is selling something.
Three things that are genuinely useful:
- Read the analyte list, not the badge. "Lab tested" is a phrase. An itemised panel naming specific compounds, tied to a batch number, is a document. Only the second one tells you anything — our COA guide shows where to look.
- Check your state. Federal scheduling and state law run on separate tracks. Several states acted before the federal notices, and a few moved further. Our overview of the federal action is at is 7-OH banned.
- Understand what the two notices actually cover. FR Doc 2026-13580 applies a threshold to 7-OH; FR Doc 2026-13581 applies none to mitragynine pseudoindoxyl, MGM-15 and MGM-16. The threshold arithmetic is in our 0.050% and 1.00 mg explainer.
What Does Not Change
The order is not retroactive. Ex post facto principles bar CSA charges for sales completed before the effective date, so nothing lawfully sold beforehand becomes a CSA offense afterwards. That is real, and it is narrow — it answers the CSA question only. Exposure under the Federal Food, Drug, and Cosmetic Act for past sales is unaffected, including the adulteration provisions at FFDCA 402(f)(1)(B), and state consumer-protection and tort law run on their own clocks.
Cat's Claw (Uncaria tomentosa) is a different plant from kratom (Mitragyna speciosa) and is not named in either notice. That is a fact about the scope of the filings, not a blanket statement about the contents of any finished product.
Where We Stand
Botanical Blends is a distributor and retailer. We carry third-party brands; we do not manufacture, formulate or blend anything. Product composition is what each brand states on its own listing, not something we assert on their behalf. The supplier certificates we hold report non-detect for 7-hydroxymitragynine and mitragynine — that is the basis for the no kratom, no mitragynine, no 7-OH framing we use, and we publish the documents on our COA page.
Those panels do not test for mitragynine pseudoindoxyl, MGM-15, MGM-16 or corynoxine B. We are not going to tell you the products we carry are free of compounds nobody looked for, and we do not describe them with blanket wording suggesting the panel covered every substance named in the notices. That is the honest state of our paperwork. Wholesale customers can see the same documentation through our wholesale page before ordering, which is how it should work.
Frequently Asked Questions
Is there any window to sell remaining stock after the effective date?
No. The order is effective on the date it publishes, and retail sale of a Schedule I substance to the general public is not permitted under the CSA. The thirty-day allowances that appear in scheduling orders apply to existing registrants and cover paperwork, not sales.
What should a retailer do with affected inventory?
Get it out of your possession lawfully before the effective date, or surrender it afterwards through a DEA-registered reverse distributor or your local DEA Diversion Control field office. After the date it cannot be sold, returned to the supplier, or exported. Talk to a lawyer — this post is not legal advice.
Can a court delay the effective date?
Not for the temporary order itself. The temporary scheduling statute states that an order issued under it is not subject to judicial review. There is no federal route to a stay of the effective date.
Does buying before August 5 protect me as a consumer?
No. The concern is possession on or after the effective date, not the purchase date. An earlier transaction does not make later possession lawful.
How long does the scheduling last?
Two years from the effective date, extendable by one additional year while permanent scheduling proceedings run. Three years is the maximum life of a temporary listing.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Legality depends on the specific formulation and applicable state law — check the rules where you live. Nothing here is legal advice.